146 related articles for article (PubMed ID: 24497572)
1. Androgen-regulated metabolism and biosynthesis in prostate cancer.
Barfeld SJ; Itkonen HM; Urbanucci A; Mills IG
Endocr Relat Cancer; 2014 Aug; 21(4):T57-66. PubMed ID: 24497572
[TBL] [Abstract][Full Text] [Related]
2. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
Vis AN; Schröder FH
BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
[TBL] [Abstract][Full Text] [Related]
3. Collocation of androgen receptor gene mutations in prostate cancer.
Buchanan G; Greenberg NM; Scher HI; Harris JM; Marshall VR; Tilley WD
Clin Cancer Res; 2001 May; 7(5):1273-81. PubMed ID: 11350894
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor action in hormone-dependent and recurrent prostate cancer.
Agoulnik IU; Weigel NL
J Cell Biochem; 2006 Oct; 99(2):362-72. PubMed ID: 16619264
[TBL] [Abstract][Full Text] [Related]
5. Expression of the forkhead transcription factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the androgen receptor in prostate cancer but is not directly regulated by androgens or hypoxia.
Banham AH; Boddy J; Launchbury R; Han C; Turley H; Malone PR; Harris AL; Fox SB
Prostate; 2007 Jul; 67(10):1091-8. PubMed ID: 17477366
[TBL] [Abstract][Full Text] [Related]
6. Molecular regulation of androgen action in prostate cancer.
Dehm SM; Tindall DJ
J Cell Biochem; 2006 Oct; 99(2):333-44. PubMed ID: 16518832
[TBL] [Abstract][Full Text] [Related]
7. Divergent androgen regulation of unfolded protein response pathways drives prostate cancer.
Sheng X; Arnoldussen YJ; Storm M; Tesikova M; Nenseth HZ; Zhao S; Fazli L; Rennie P; Risberg B; Wæhre H; Danielsen H; Mills IG; Jin Y; Hotamisligil G; Saatcioglu F
EMBO Mol Med; 2015 Jun; 7(6):788-801. PubMed ID: 25864123
[TBL] [Abstract][Full Text] [Related]
8. HOXC8 inhibits androgen receptor signaling in human prostate cancer cells by inhibiting SRC-3 recruitment to direct androgen target genes.
Axlund SD; Lambert JR; Nordeen SK
Mol Cancer Res; 2010 Dec; 8(12):1643-55. PubMed ID: 21047772
[TBL] [Abstract][Full Text] [Related]
9. The androgen receptor DNA-binding domain determines androgen selectivity of transcriptional response.
Verrijdt G; Tanner T; Moehren U; Callewaert L; Haelens A; Claessens F
Biochem Soc Trans; 2006 Dec; 34(Pt 6):1089-94. PubMed ID: 17073757
[TBL] [Abstract][Full Text] [Related]
10. The importance of steroid hormones in prostate cancer.
Wilding G
Cancer Surv; 1992; 14():113-30. PubMed ID: 1423327
[TBL] [Abstract][Full Text] [Related]
11. Regulation of FGF8 expression by the androgen receptor in human prostate cancer.
Gnanapragasam VJ; Robson CN; Neal DE; Leung HY
Oncogene; 2002 Aug; 21(33):5069-80. PubMed ID: 12140757
[TBL] [Abstract][Full Text] [Related]
12. Androgen signaling and its interactions with other signaling pathways in prostate cancer.
Kaarbø M; Klokk TI; Saatcioglu F
Bioessays; 2007 Dec; 29(12):1227-38. PubMed ID: 18008377
[TBL] [Abstract][Full Text] [Related]
13. Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails.
Niu Y; Chang TM; Yeh S; Ma WL; Wang YZ; Chang C
Oncogene; 2010 Jun; 29(25):3593-604. PubMed ID: 20440270
[TBL] [Abstract][Full Text] [Related]
14. Myc-dependent purine biosynthesis affects nucleolar stress and therapy response in prostate cancer.
Barfeld SJ; Fazli L; Persson M; Marjavaara L; Urbanucci A; Kaukoniemi KM; Rennie PS; Ceder Y; Chabes A; Visakorpi T; Mills IG
Oncotarget; 2015 May; 6(14):12587-602. PubMed ID: 25869206
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of prostate cancer cell survival after inhibition of AR expression.
Cohen MB; Rokhlin OW
J Cell Biochem; 2009 Feb; 106(3):363-71. PubMed ID: 19115258
[TBL] [Abstract][Full Text] [Related]
16. The role of the androgen receptor in the development and progression of prostate cancer.
Jenster G
Semin Oncol; 1999 Aug; 26(4):407-21. PubMed ID: 10482183
[TBL] [Abstract][Full Text] [Related]
17. Regulator of G-protein signaling 2 (RGS2) inhibits androgen-independent activation of androgen receptor in prostate cancer cells.
Cao X; Qin J; Xie Y; Khan O; Dowd F; Scofield M; Lin MF; Tu Y
Oncogene; 2006 Jun; 25(26):3719-34. PubMed ID: 16449965
[TBL] [Abstract][Full Text] [Related]
18. FOXP1 is an androgen-responsive transcription factor that negatively regulates androgen receptor signaling in prostate cancer cells.
Takayama K; Horie-Inoue K; Ikeda K; Urano T; Murakami K; Hayashizaki Y; Ouchi Y; Inoue S
Biochem Biophys Res Commun; 2008 Sep; 374(2):388-93. PubMed ID: 18640093
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer.
Ragnum HB; Røe K; Holm R; Vlatkovic L; Nesland JM; Aarnes EK; Ree AH; Flatmark K; Seierstad T; Lilleby W; Lyng H
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):753-60. PubMed ID: 24035332
[TBL] [Abstract][Full Text] [Related]
20. Androgen regulation of gene expression.
Lamont KR; Tindall DJ
Adv Cancer Res; 2010; 107():137-62. PubMed ID: 20399963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
